45 results on '"Colonno, Richard"'
Search Results
2. Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection
3. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
4. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
5. Development of a highly sensitive multiplex platform assay to monitor low levels of HBV DNA and pgRNA in samples from patients with chronic hepatitis B
6. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
7. Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
8. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
9. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
10. LBP-12-Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers
11. THU-216-Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough
12. PS-073-Preclinical profile of HBV core protein inhibitor, ABI-H, a potent inhibitor of cccDNA generation in HBV infected cells
13. LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
14. Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold
15. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4
16. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound
17. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor
18. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors
19. Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs
20. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies
21. Utilization of in vitro Caco‐2 permeability and liver microsomal half‐life screens in discovering BMS‐488043, a novel HIV‐1 attachment inhibitor with improved pharmacokinetic properties
22. Corrigendum to “Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns” [Bioorg. Med. Chem. Lett. 19 (2009) 1977]
23. Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns
24. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
25. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
26. Corrigendum to “Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability” [Bioorg. Med. Chem. Lett. 17 (2007) 895–901]
27. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir
28. Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability
29. Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
30. A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients
31. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus
32. Differential effect of modified capped RNA substrates on influenza virus transcription
33. Characterization of a Hemagglutinin-Specific Inhibitor of Influenza A Virus
34. Stimulation of the Herpes Simplex Virus Type I Protease by Antichaeotrophic Salts
35. Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein
36. α-hydroxyamide derived aminodiols as potent inhibitors of hiv protease
37. Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors
38. Domains 1 and 2 of ICAM-1 are sufficient to bind human rhinoviruses
39. The major and minor group receptor families contain all but one human rhinovirus serotype
40. Avian cells expressing the murine Mx1 protein are resistant to influenza virus infection
41. Mapping and initiation studies on the leader RNA of vesicular stomatitis virus
42. Modification of experimental rhinovirus colds by receptor blockade
43. A unique RNA species involved in initiation of vesicular stomatitis virus RNA transcription in vitro
44. Complete nucleotide sequence of the leader rna synthesized in vitro by vesicular stomatitis virus
45. Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.